Abbott Labs (ABT) PT Raised to $132 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts ABT Hot Sheet
Price: $104.57 +1.88%
Rating Summary:
26 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 1 | Down: 18 | New: 0
Rating Summary:
26 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 1 | Down: 18 | New: 0
Join SI Premium – FREE
Barclays analyst Matt Miksic raised the price target on Abbott Labs (NYSE: ABT) to $132.00 (from $127.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Argus Downgrades Abbott Labs (ABT) to Hold
- Abbott launches next-generation Oncodetect cancer MRD blood test
- Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
